Upstream process intensification using perfusion cell culture has become a necessity for meeting today’s demand in monoclonal antibodies (mAbs) bioprocessing. By sustaining higher viable cell ...
The FDA recently announced its plan to phase out the animal testing requirement for monoclonal antibodies (mAbs) and other drugs, instead opting to use human-relevant new approach methodologies (NAMs) ...
Therapeutic antibodies will always be too expensive for low- and middle-income countries, unless manufacturers embrace more cost-efficient production tech. So says Peter Gardner, scientific director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results